Convertissez First Digital USD FDUSD en VitaStem VITASTEM

What is the project about? First Digital USD (FDUSD) aim to revolutionize the digital asset landscape. Our mission is to empower users with a transformative financial instrument that combines the stability of cash reserves with the seamless efficiency of advanced blockchain technology. By offering a fully collateralized digital asset, our stablecoin ensures the utmost security, transparency, and transaction reliability. This strategic fusion of traditional stability and cutting-edge innovation allows users to confidently navigate the digital economy, unlocking a world of possibilities while maintaining the utmost trust in their financial interactions. What makes your project unique? Transferable: FDUSD enables frictionless and streamlined transactions, rendering it a convenient choice for a wide range of applications and scenarios. Redeemable: FDUSD is backed by high-quality reserves- cash and cash equivalents, which enable holders the ability to redeem their FDUSD tokens for their equivalent value in US dollars. Users can trust that FDUSD is always 1:1 backed. Low Fees: One notable benefit of FDUSD is its ability to offer cost-effective transactions with minimal fees. Unlike traditional financial transactions, this cost-efficiency makes FDUSD an attractive and economical choice for users. Operates on Decentralized Networks. FDUSD operates on decentralized networks that are distributed across multiple nodes. In so doing, it enhances transparency, security, and resilience. Bankruptcy Remote FDUSD is designed to be bankruptcy remote, with the reserves held in segregated accounts on a registered trust company, separated from the issuer’s operational accounts. It ensures the stablecoin remains stable and secure. History of your project. Established in 2019, First Digital is Asia’s leading multi-faceted trust partner bridging the gap between the traditional and digital financial worlds.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.